Eczema Patients Have Lost Faith In Treatment: Survey
"); jQuery("#212 h3").html("

"); });
2022-09-13 HKT 20:53
A international survey has found that only 37 percent of eczema patients in the city are working on treatment plans with doctors, while two-thirds have lost hope.
GlobalSkin, an international alliance of dermatology patient organisations, initiated the study covering 330 eczema patients in the SAR, South Korea and Australia in August, with one-third of the respondents in Hong Kong.
Dermatologist Dr Johnny Chan said on Tuesday that the proportion of patients in the city seeking medical advice is “very low”.
He said more than 90 percent of them are being treated by public practitioners, but strained medical resources due to the Covid-19 pandemic have delayed their treatment.
“The queue time of every [eczema] treatment will be two to three years at the moment," he said, adding that does not taken into account the impact Covid has had on waiting times even longer.
“While they are waiting, they think the treatments will not be helping them, and may lose the faith in treatment. They think it’s just incurable, they don’t want to have any treatment anymore,” Chan said.
“Public doctors have a limited time to see a lot of patients every day."
But for moderate to severe cases, he said, "they need some more time for explanations about the disease nature: to have a more tailor-made treatment plan for the patients, and to explain any possible side effects and the way to avoid these side effects.”
Chan added that less than 10 percent of eczema sufferers had sought treatment from the private sector. He said high costs was "very much an issue" here, with 72 percent of patients saying the heavy financial burden had deterred them from visiting doctors.
Dr Marco Ho, who chairs the Hong Kong Allergy Association, said when treatment is delayed, a patients’ immune system further deregulates and their conditions worsen, hence their expectations in consultations can be over-optimistic.
“Sometimes you don’t have the best-matched medication treatment as well as therapies. They have a whole lot of ideas and their own personal belief, so end up when we say ‘control’, they say ‘cure’; when we say ‘short-term gain’, they want a ‘long-term' remission,” he said.
“At times we even think the patient needs hospitalisation [but] they can't afford to stop their work or school.”
To clear up such misinterpretations and handle mental problems when patients are suffering from skin conditions, the allergy association and a concern group under the Hong Kong Health Care Alliance launched a free online counseling service on Tuesday that will run for three months.
ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education
ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more
Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets
The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more
Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation
Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more
MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending
MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more
Why The $2 Trillion Stablecoin Prediction Is Too Low
McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more
RedotPay Eyes US IPO With Potential US$1 Billion Raise
RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more